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ABSTRACT
Objectives: To describe how systematic reviewers are
reporting missing data for dichotomous outcomes,
handling them in the analysis and assessing the risk of
associated bias.
Methods: We searched MEDLINE and the Cochrane
Database of Systematic Reviews for systematic reviews
of randomised trials published in 2010, and reporting a
meta-analysis of a dichotomous outcome. We
randomly selected 98 Cochrane and 104 non-Cochrane
systematic reviews. Teams of 2 reviewers selected
eligible studies and abstracted data independently and
in duplicate using standardised, piloted forms with
accompanying instructions. We conducted regression
analyses to explore factors associated with using
complete case analysis and with judging the risk of
bias associated with missing participant data.
Results: Of Cochrane and non-Cochrane reviews, 47%
and 7% (p<0.0001), respectively, reported on the
number of participants with missing data, and 41%
and 9% reported a plan for handling missing
categorical data. The 2 most reported approaches for
handling missing data were complete case analysis
(8.5%, out of the 202 reviews) and assuming no
participants with missing data had the event (4%). The
use of complete case analysis was associated only with
Cochrane reviews (relative to non-Cochrane: OR=7.25;
95% CI 1.58 to 33.3, p=0.01). 65% of reviews
assessed risk of bias associated with missing data; this
was associated with Cochrane reviews (relative to non-
Cochrane: OR=6.63; 95% CI 2.50 to 17.57, p=0.0001),
and the use of the Grading of Recommendations
Assessment, Development and Evaluation (GRADE)
methodology (OR=5.02; 95% CI 1.02 to 24.75,
p=0.047).
Conclusions: Though Cochrane reviews are
somewhat less problematic, most Cochrane and non-
Cochrane systematic reviews fail to adequately report
and handle missing data, potentially resulting in
misleading judgements regarding risk of bias.
BACKGROUND
Although clinical trial investigators may strive
to reduce the amount of missing data, they
will in most instances fail to achieve com-
plete follow-up.1 2 In a recent survey of the
top ﬁve general medical journals, 87% of
published trials reported participants with
missing data for the primary outcome.3 The
median percentage of participants with
missing data was 6% (IQR 2–14%).3
Moreover, the way the trials handled missing
participant data varied and was unclear in
about a ﬁfth of reports.3
The Cochrane Collaboration Handbook
and the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses
(PRISMA) statement recommend that the
systematic review authors provide a descrip-
tion of incomplete reporting of data in the
included trials.4 5 Furthermore, they
Strengths and limitations of this study
▪ This is the first study to assess the reporting,
handling and assessment of risk of bias asso-
ciated with missing participant data among sys-
tematic reviews.
▪ The study used systematic, rigorous and trans-
parent approaches to define eligibility criteria,
search for eligible studies, select studies and
abstract data.
▪ The broad eligibility criteria and inclusion of both
Cochrane and non-Cochrane systematic reviews
make the results more generalisable.
▪ One limitation of the study is the restriction of
our search to MEDLINE database.
▪ The study did not analyse the individual trials
that contributed to eligible systematic reviews.
Akl EA, et al. BMJ Open 2015;5:e009368. doi:10.1136/bmjopen-2015-009368 1
Open Access Research
group.bmj.com on May 11, 2016 - Published by http://bmjopen.bmj.com/Downloaded from 
recommend reporting how missing data are incorpo-
rated into the review ﬁndings. Although the Cochrane
Handbook encourages the reanalysis of a study’s effect
estimate by including all randomised participants, it
lacks a detailed guidance on how to handle missing
data.4
The Grading of Recommendations Assessment,
Development and Evaluation (GRADE) approach to
judging the conﬁdence in pooled effect estimates takes
into account the risk of bias associated with missing
data.6 The Cochrane Collaboration Handbook and
PRISMA statement recommend that the authors of sys-
tematic reviews clearly describe how they assessed the
risk of bias associated with missing data.4 5 The
Cochrane Handbook describes situations in which an
analysis can be judged to be at low or high risk of bias.
For example, exclusion of participants due to ‘inefﬁcacy’
or ‘failure to improve’ would be judged as introducing a
high risk of bias.
There is a need to better understand how systematic
review authors handle missing participant data in system-
atic reviews. Therefore, the primary objective of this
methodological survey was to describe how systematic
review authors report, handle and judge the risk of bias
associated with missing data for dichotomous outcomes.
Given the evidence that Cochrane reviews tend to be of
higher methodological quality compared with other
reviews,7 8 our secondary objective was to investigate dif-




This study is part of a larger project (the ARROW
project) examining methodological issues in systematic
reviews; we have reported the full details of the method-
ology elsewhere.9 We used standard systematic review
methods to survey how Cochrane and non-Cochrane sys-
tematic reviews report, handle and judge the risk of bias
associated with missing participant data. We deﬁned
Cochrane systematic reviews as systematic reviews pub-
lished in the Cochrane Database of Systematic Reviews. We
considered all other systematic reviews as non-Cochrane
systematic reviews. Since no human participants were
involved, ethical approval was not required. The
Cochrane Methods Innovation Fund funded this project.
Eligibility criteria
Eligible studies met the following inclusion criteria:
described as a meta-analysis or a systematic review;
describes a search strategy of at least one electronic data-
base; published in the Cochrane Database of Systematic
Reviews or in a journal indexed in MEDLINE;4 includes
randomised controlled trials comparing an intervention
with another intervention or with no intervention (or
placebo) in humans; and reports measures of effect for
at least one dichotomous outcome either from a single
study or from a pooled analysis.
Search strategy
We conducted the searches in the MEDLINE database
through the OVID interface (see online supplementary
appendix S1). For non-Cochrane systematic reviews, we
employed a systematic review ﬁlter designed by the
Health Information Research Unit of McMaster
University.10 For Cochrane systematic reviews, we
restricted the search results to the Cochrane Database of
Systematic Reviews as the journal type. We limited the
searches to the year 2010. We used no language
restrictions.
Selection process
We conducted the selection process for Cochrane and
non-Cochrane reviews separately. Of the search results,
we screened consecutive citations in a random order
until we included the target sample size, with approxi-
mately equal representation of Cochrane and
non-Cochrane reviews.
Teams of two reviewers conducted title and abstract
screening independently and in duplicate. We obtained
the full texts of citations judged as potentially eligible by
at least one reviewer. The same teams of reviewers con-
ducted full text screening. They resolved discrepancies
by consensus, and when unsuccessful, with the help of a
third reviewer. Reviewers participated in calibration exer-
cises and used standardised and pilot-tested forms with
detailed written instructions. They selected for each
study a pairwise comparison and the most patient-
important outcome.9 We deﬁned a patient-important
outcome as an outcome for which one would answer
with ‘yes’ the following question: ‘If the patient knew
that this outcome was the only thing to change with
treatment, would the patient consider receiving this
treatment if associated with side effects or cost?’.11 The
patient-important outcome did not necessarily have to
be the primary outcome.9 We used an online systematic
review software application (DistillerSR, Evidence
Partners, Ottawa, Canada; http://systematic-review.net/)
to facilitate screening and data abstraction.
Data abstraction
Teams of two reviewers abstracted data using DistillerSR.
They resolved discrepancies by consensus, and when
unsuccessful, with the help of a third reviewer. They par-
ticipated in calibration exercises, and used standardised
and pilot-tested forms with detailed instructions.
We abstracted information about the following general
characteristics of the systematic review:
▸ Number of included trials;
▸ Number of included participants in intervention and
control arms;
▸ Quality of the systematic review using the ‘assessment
of multiple systematic reviews’ (AMSTAR) tool.12 The
tool consists of 11 questions with 4 answer options
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(yes, no, can’t answer, not applicable). The score for
each study consisted of the number of ‘yes’ answers,
with higher values indicating better scores (0–4: low
quality; 5–8: moderate quality; 9–11 high quality);
▸ Type of intervention (pharmacological vs surgery/
invasive procedure);
▸ Type of meta-analysis (standard meta-analysis vs
meta-regression vs individual participant data
meta-analysis);
▸ Evaluation of the risk of bias (using Cochrane Risk of
Bias (RoB) tool vs by dimensions vs point system
scale);
▸ Use of the GRADE approach to rate conﬁdence in
effect estimates;13
▸ Source of funding (for proﬁt source vs source other
than for proﬁt vs not funded);
▸ Whether any of the authors reports industry ties.
We abstracted the following information regarding the
collection and reporting of information about missing
participant data within each systematic review:
▸ Plan to collect the number of participants with
missing data;
▸ Plan to collect the reasons for missing participant
data;
▸ Reporting of the number of participants with missing
data;
▸ Reporting of categories for participants with missing
data (eg, withdrawal of consent, cross-over, dropouts,
non-adherence);
▸ Reporting on missing participant data as a separate
outcome;
▸ Inclusion of information on missing data in tabular
format.
We abstracted data on how each systematic review
handled missing participant data:
▸ Plan for handling missing categorical data;
▸ Plan for sensitivity analysis using different methods
for handling missing participant data;
▸ Provision of a justiﬁcation for the method(s) for
handling missing participant data.
We also assessed whether the authors judged the risk of
bias associated with missing participants using a speciﬁc
tool as such as the Cochrane RoB tool. Finally, we assessed
whether the implications of missing participant data were
incorporated in the Results or Discussion sections.
Analysis
We conducted a descriptive analysis of all variables. We
used frequencies and percentages for categorical vari-
ables, and median and IQR for continuous variables as
these data were not normally distributed. We analysed
the data combined as well as stratiﬁed by type of review
(Cochrane vs non-Cochrane). For this stratiﬁcation, we
compared continuous variables using the independent t
test or Wilcoxon test depending on the distribution of
the data. We compared categorical variables using the
χ2 test or Fisher’s exact test if the expected event
number is less than 5.
We conducted two multivariable logistic regression
analyses and prespeciﬁed the following dependent vari-
ables: (1) whether the systematic reviewers used com-
plete case analysis; and (2) whether the systematic
reviewers judged the risk of bias associated with missing
participant data. We included the following independent
variables in our adjusted models: type of review
(Cochrane vs non-Cochrane); number of included trials;
type of intervention; use of the GRADE approach to rate
conﬁdence in effect estimates; and whether any of the
authors reported ties to industry. Following descriptive
analyses, we omitted the latter two independent vari-
ables from the ﬁrst regression analysis due to the low
number of events. We hypothesised that Cochrane
reviews and the use of the GRADE approach, but not
industry ties, would be associated with the use of com-
plete case analysis and judgement of the risk of bias asso-
ciated with missing data. We used SPSS statistical
software, V.18.0 (SPSS INC, Chicago, Illinois, USA).
Sample size calculation
We originally calculated the sample size for the purpose
of evaluating the association of study characteristics with
the reporting of absolute effects (the ARROW project).9
As we used the same sample (N=202) to conduct the
current study, we estimated whether its size would be
appropriate for a regression analysis to study the associ-
ation of study characteristics with using complete case
analysis. The regression analysis includes ﬁve independ-
ent variables, and would require 10 events per variable.
As we were not aware of studies providing an estimate
for the dependent variable, we considered a conservative
estimate of 30%. The resulting sample size is 167,
making the 202 systematic reviews sample we have large
enough for our purpose.
RESULTS
Out of 2328 citations identiﬁed by the search strategy,
we included a total of 202 systematic reviews: 98
Cochrane and 104 non-Cochrane reviews (ﬁgure 1).
Table 1 reports the general characteristics of included
studies, with a p value for the test of difference between
these two types. Cochrane reviews included fewer trials
and participants, less frequently conducted
meta-regression, had a higher AMSTAR score, but more
frequently addressed pharmacological interventions,
assessed risk of bias, and used the GRADE approach for
rating certainty in estimates.
Reporting missing participant data
Table 2 reports the collection and reporting of informa-
tion about missing participant data in the included sys-
tematic reviews. The percentages of reviews that
reported plans for collecting the number and reasons
for missing data were 34% and 17%, respectively. The
percentages that actually reported the number and cat-
egories with potentially missing participant data were
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26% and 19%, respectively. Five per cent of systematic
reviews reported missing participant data as an outcome
measure. About half of the reviews included information
about missing participant data in a tabular format.
Cochrane reviews compared favourably to non-Cochrane
reviews for all these reporting variables.
Handling missing participant data
Table 3 shows the characteristics of systematic reviews in
terms of handling missing participant data. The percent-
age of systematic reviews reporting a plan for handling
missing categorical data was 25%. The two most
reported approaches were using complete case analysis
and assuming no participants with missing data had the
event (8.5% and 4%, respectively, of all 202 reviews).
A small percentage of reviews (11%) reported a planned
sensitivity analysis using different method(s) for hand-
ling missing participant data, with only 2% providing a
justiﬁcation for those methods.
In our multivariable logistic regression, whether the
systematic review used complete case analysis was asso-
ciated only with the type of review (Cochrane vs
non-Cochrane: OR=7.25; 95% CI 1.58 to 33.3, p=0.01).
The variables for which no statistically signiﬁcant associa-
tions were identiﬁed were: number of included trials
and type of intervention.
Assessing risk of bias associated with missing
participant data
Table 3 describes the assessment of the risk of bias asso-
ciated with missing participant. Of all included system-
atic reviews, 65% reported assessing risk of bias
associated with missing data: 42% used the Cochrane
RoB tool; 23% used a tool other than the Cochrane RoB
tool. Differences between Cochrane and non-Cochrane
reviews were statistically signiﬁcant (p<0.0001). Eleven
per cent of included reviews discussed the implications
of missing participant data in the Results section, and
10% addressed them in the Discussion section.
In our multivariable logistic regression, whether the
systematic review judged the risk of bias associated with
missing participant data was associated with Cochrane
versus non-Cochrane type (OR=6.63; 95% CI 2.50 to
17.57, p=0.0001), and whether the systematic review
used the GRADE approach to rate the conﬁdence in
effect estimates (OR=5.02; 95% CI 1.02 to 24.75,
p=0.047). The variables for which no statistically signiﬁ-
cant associations were identiﬁed were: number of
included trials, type of intervention and whether any of
the authors reported ties to industry.
DISCUSSION
Although Cochrane systematic reviews are less problem-
atic, most Cochrane and non-Cochrane reviews do not
adequately report and handle missing data. In general,
50% or less of Cochrane reviews met the criteria we
explored, versus 20% or less of non-Cochrane reviews.
Only 13% of reviews reported planned sensitivity ana-
lyses for handling missing participant data. Reporting on
risk of bias associated with missing participant data was
the least problematic item (65%). Better performance
was associated with Cochrane versus non-Cochrane type,
and whether the systematic review used the GRADE
approach to rate conﬁdence in effect estimates.
Our study has a number of strengths. This is the ﬁrst
study that assesses the reporting, handling and
Figure 1 Flow chart of the
screening literature process (RCT,
randomised controlled trial).
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assessment of risk of bias associated with missing partici-
pant data among systematic reviews. We used explicit eli-
gibility criteria, and sensitive search strategies to identify
eligible studies. We also employed systematic, rigorous
and transparent approaches to study selection and data
abstraction, including calibration exercises, duplicate
processes and use of standardised pilot-tested forms with
detailed instructions. We included both Cochrane and
non-Cochrane systematic reviews and used broad eligibil-
ity criteria to make our results more generalisable.
The main limitation of our study is that we did not
review the individual trials that contributed to eligible
systematic reviews, and the very low percentage of sys-
tematic reviews reporting on potential reasons for
missing data might be due to the poor reporting of such
information at the trial level. While the restriction of
our search to MEDLINE database could have affected
the representativeness of systematic reviews, we believe
the included reviews represent those typically accessed
by clinicians.
Although all reviews performed poorly in terms of
reporting, Cochrane reviews performed better than
non-Cochrane reviews. Likely explanations include the
availability of a methodological guidance (ie, the
Cochrane Handbook), and the use of standardised
tables in Cochrane (ie, the Cochrane RoB tool). Another
potential explanation is the lack of space constraints for
the publication of Cochrane systematic reviews. It is
important to note that non-Cochrane reviews are likely to
be a highly heterogeneous in terms of methodological
and reporting characteristics. Unfortunately, our study
lacked the power to explore that hypothesis.
A recent study examined how 100 Cochrane systematic
reviews and 100 non-Cochrane systematic reviews pub-
lished in 2012 assessed risk of bias of primary studies
and incorporated them into their statistical analysis and
overall ﬁndings.7 The investigators found that incom-
plete outcome data, deﬁned as missing outcome data
due to attrition, were reported in 95% of Cochrane
reviews compared with 61% of non-Cochrane reviews.





SR (N=104) p Value*
Number of included trials; median (IQR) 5 (2–9) 3 (2–8) 6 (4–9) <0.0001
Number of participants in intervention group; median
(IQR)
426.5 (127–1141) 289 (103–794) 660 (221–1924) 0.006
Number of participants in control group; median (IQR) 418 (117–1026) 271 (85–657) 646 (212–1773) 0.002
AMSTAR score; median (IQR)† 9 (7–10) 10 (9–10) 7 (6–8.5) <0.0001
Intervention
Pharmacological 130 (64.4%) 70 (71.4%) 60 (57.7%) 0.074
Surgery/invasive procedure 33 (16.3%) 15 (15.3%) 18 (17.3%)
Other 39 (19.3%) 13 (13.3%) 26 (25%)
Type of meta-analysis
Standard meta-analysis 186 (92.1%) 88 (89.8%) 98 (94.2%) 0.30
Metaregression 18 (8.9%) 3 (3%) 15(14.4%) 0.006
Individual participant data meta-analysis 7 (3.4%) 2 (2%) 5 (4.8%) 0.45
Other 10 (5%) 7 (7.1%) 3 (2.9%) 0.204
Evaluation of the risk of bias <0.0001
Using the Cochrane Risk of Bias tool 94 (46.5%) 84 (85.7%) 10 (9.6%)
By dimensions (eg, blinding) 39 (19.3%) 8 (8.2%) 31 (29.8%)
Using Jadad’s or other point system scale 37 (18.3%) 4 (4.1%) 33 (31.7%)
Not done 18 (8.9%) 0 (0%) 18 (17.3%)
Used the GRADE approach to rate confidence in
effect estimates
32 (15.8%) 27 (27.6%) 5 (4.8%) <0.0001
Funding
For profit source 7 (3.5%) 2 (2%) 5 (4.8%) 0.45
Source other than for profit 99 (49%) 63 (64.3%) 36 (34.6%) <0.0001
Not funded 23 (11.4%) 9 (9.2%) 14 (13.5%) 0.34
Not reported 72 (35.6%) 23 (23.5%) 49 (47%) 0.0005
Reported industry ties by authors <0.0001
Yes 37 (18.3%) 19 (19.4%) 18 (17.3%)
No 95 (47.0%) 60 (61.2%) 35 (33.7%)
Not reported 68 (33.7%) 19 (19.4%) 49 (47.1%)
Unclear 2 (1.0%) 0 (0%) 2 (1.9%)
*p Value for the difference between Cochrane and non-Cochrane SRs.
†AMSTAR interpretation: 0–4: low quality; 5–8: moderate quality; 9–11 high quality.
AMSTAR, assessment of multiple systematic reviews; SR, systematic review.
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We found substantially lower ﬁgures that are probably
related to lower percentage of reviews using the GRADE
approach in our sample (16% vs 45%).
That study found that 8% and 1% of Cochrane and
non-Cochrane reviews, respectively, assessed incomplete
outcome data for more than one outcome. In our study,
we assessed whether the systematic reviews reported the
number of participants with missing data for each
outcome. The percentages were similarly very low at 2%
and 0% for Cochrane and non-Cochrane reviews,
respectively. This is problematic because missingness of
data may actually vary across outcomes (eg, due to differ-
ent follow-up times for different outcomes).
We recently suggested a simple guidance for addressing
dichotomous data for participants excluded from analyses
of randomised trials and for assessing the associated risk of
bias.14 Brieﬂy, the guidance suggests for the primary ana-
lysis, either a complete case analysis or making plausible
assumptions about the outcomes of participants with
missing data. When the primary analysis suggests import-
ant beneﬁt, the guidance recommends sensitivity
meta-analyses using relatively extreme assumptions that
may vary in plausibility to assess the associated risk of bias.
We have developed a similar guidance for continuous
data, including situations where continuous data are mea-
sured with different instruments.15 16 Other authors have
similarly published recommendations for addressing
missing data in meta-analysis.17–20 Our ﬁndings highlight
the need for better compliance with and enforcement of
the Cochrane Collaboration Handbook and the PRISMA
statement’s recommendations related to reporting of
missing participant data.4 5 This would be facilitated by
better reporting of missing data at the trial level,21 given
the systematic review authors can typically rely on what the
authors of primary studies report, as well as easing of space
constraints in reporting, of non-Cochrane reviews in par-
ticular. Systematic reviewers also need to assess the risk of
bias associated with missing participant data, and how it
affects the conﬁdence in the effects estimates.
The ﬁndings have also implications for methodo-
logical research. A number of approaches for handling
missing data in meta-analysis are available.14–20 We now






SR (N=104) p Value*
Reported a plan to collect number of participants with missing
data
68 (33.7%) 51 (52%) 17 (16.3%) <0.0001
Reported a plan to collect reasons for missing data 35 (17.3%) 26 (26.5%) 9 (8.7%) 0.0008
Reported number of participants with missing data
No 149 (73.8%) 52 (53.1%) 97 (93.3%) <0.0001
Across comparisons, but not for each comparison 14 (7.0%) 11 (11.2%) 3 (2.9%) 0.03
For each comparison, but not for each study 3 (1.5%) 2 (2.0%) 1 (1.0%) 0.61
For each study but not for each outcome 34 (16.8%) 31 (31.6%) 3 (2.9%) <0.0001
For each outcome 2 (1.0%) 2 (2.0%) 0 (0%) 0.23
Reported on the following participant categories with potentially missing data
No reporting of any category 163 (80.7%) 66 (67.4%) 97 (93.3%) <0.0001
Mistakenly randomised 6 (3.0%) 6 (6.1%) 0 (0%) 0.01
Did not receive intervention 4 (2.0%) 4 (4.1%) 0 (0%) 0.05
Withdrew consent 12 (6.0%) 11 (11.2%) 1 (1.0%) 0.002
Crossed over 0 (0%) 0 (0%) 0 (0%) –
Dropped out 21 (10.4%) 16 (16.3%) 5 (4.8%) 0.007
Non-adherent 7 (3.5%) 7 (7.1%) 0 (0%) 0.006
Lost contact 14 (6.9%) 13 (13.3%) 1 (1%) <0.0001
‘Other reasons’ not otherwise specified 6 (3.0%) 5 (5.0%) 1 (1.0%) 0.11
Other specified reason 10 (5.0%) 10 (10%) 0 (0%) <0.0001
SR authors reported that included studies did not report on
missing data
3 (1.5%) 3 (3.1%) 0 (0%) 0.11
Reported on missing data as distinct outcome 9 (4.5%) 8 (8.2%) 1 (1.0%) 0.02
Reported information on missing data in
Cochrane RoB tool (table format) 61 (30.2%) 59 (60.2%) 2 (1.9%) <0.0001
Cochrane RoB tool (graph format) 46 (22.77%) 45 (45.92%) 1 (1.0%) <0.0001
GRADE SoF table 9 (4.5%) 9 (9.2%) 0 (0.0%) 0.001
GRADE EP 0 (0.0%) 0 (0.0%) 0 (0.0%) –
Table describing characteristics of included studies 70 (34.7%) 61 (62.2%) 9 (8.7%) <0.0001
Other table 9 (4.5%) 2 (2.0%) 7 (6.7%) 0.17
None of the above 102 (50.5%) 17 (17.4%) 85 (81.7%) <0.0001
*p Value for the difference between Cochrane and non-Cochrane SRs.
EP, Evidence Profile; GRADE, Grading of Recommendations Assessment, Development and Evaluation; RoB, Risk of Bias; SoF, Summary
of Findings; SR, systematic review.
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need to compare the impact of these methods on the
statistical signiﬁcance of pooled effect estimates and on
the associated quality of evidence.
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SR (N=104) p Value*
Reported plans for handling missing categorical data <0.0001
Using complete case analysis 17 (8.5%) 15 (15.5%) 2 (2.0%)
Assuming no participants with missing data had the event 8 (4.0%) 7 (7.2%) 1 (1.0%)
Assuming all participants with missing data had the event 5 (2.5%) 4 (4.1%) 1 (1.0%)
Assuming participants with missing data had same event rate
as those followed up in respective randomisation groups
2 (1.0%) 1 (1.0%) 1 (1.0%)
Using worst case scenario† 0 (0.0%) 0 (0.0%) 0 (0.0%)
Using best case scenario‡ 1 (0.5%) 0 (0.0%) 1 (1.0%)
Using whatever assumptions the included trials used 1 (0.5%) 1 (1.0%) 0 (0.0%)
Using other assumption(s) 15 (7.5%) 12 (12.4%) 3 (3.0%)
No method described 150 (75.4%) 57 (58.8%) 93 (91.2%)
Reported a planned sensitivity analyses for handling missing participant data
Yes, clearly for categorical outcomes 12 (5.9%) 10 (10.2%) 2 (1.9%) 0.02
Yes, but unclear as to whether for categorical or continuous
outcomes
11 (5.4%) 9 (9.2%) 2 (1.9%) 0.03
Provide a justification for any of the method(s) for handling
missing participant data
4 (2.0%) 4 (4.2%) 0 (0.0%) <0.0001
Assessed the risk of bias associated with missing participant data
Yes, using the Cochrane RoB tool (incomplete outcome data
(attrition bias))
85 (42.1%) 76 (77.6%) 9 (8.7%) <0.0001
Yes, using a tool other than the Cochrane RoB tool (eg, Jadad’s
scale)
47 (23.3%) 6 (6.1%) 41 (39.4%)
Discussed the implications of missing participant data
Yes, in the Results section 23 (11.4%) 19 (19.4%) 4 (3.9%)
Yes, in the Discussion section 20 (10.0%) 16 (16.3%) 4 (3.9%)
*p Value for the difference between Cochrane and non-Cochrane SRs.
†Worst case scenario: assuming all participants with missing data in the intervention group had the event but none in the control group did.
‡Best case scenario: assuming that all participants with missing data in the control group had the event but none in the intervention group
did.
RoB; Risk of Bias; SR, systematic review.
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